Frontier
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. May 28, 2013; 19(20): 2979-2984
Published online May 28, 2013. doi: 10.3748/wjg.v19.i20.2979
Expert opinion: Experience with 6-mercaptopurine in the treatment of inflammatory bowel disease
Burton I Korelitz
Burton I Korelitz, Clinical Research in Gastroenterology, Division of Gastroenterology, Department of Medicine, Lenox Hill Hospital, New York, NY 10075, United States
Author contributions: Korelitz BI solely contributed to this paper.
Correspondence to: Burton I Korelitz, MD, Chief Emeritus, Director of Clinical Research in Gastroenterology, Division of Gastroenterology, Department of Medicine, Lenox Hill Hospital, New York, NY 10075, United States. bkorelitz@nshs.edu
Telephone: +1-212-4342063 Fax: +1-212-4342446
Received: December 26, 2012
Revised: April 9, 2013
Accepted: April 17, 2013
Published online: May 28, 2013
Core Tip

Core tip: Calculation of dose, utilization of serological tests, maintenance therapy, desensitization to 6-mercaptopurine (6-MP), toxicity to 6-MP, post-operative prevention, extraintestinal manifestations, perirectal fistulas and other fistulas, pregnancy, role of biologicals in management, brand name vs generic 6-MP and azathioprine.